• Posted on: 13 April 2018
  • By: thessalus

Studio sul profilo delle lipoproteine, Lp-PLA2 e fattore di rischio cardiovascolare in pazienti in emodialisi.

Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients

Roberta Rolla, Andreana De Mauri, Ambra Valsesia, Matteo Vidali, Doriana Chiarinotti & Giorgio Bellomo

Journal of Nephrology

ISSN 1121-8428


Background Cardiovascular disease is the leading cause of morbidity and mortality in hemodialysis patients; the increased risk of cardiovascular disease is due to acceler- ated atherosclerosis, inflammation and impaired lipoprotein metabolism. We aimed to evaluate lipoprotein-associated phospholipase A2 (Lp-PLA2) and some pro-inflammatory aspects of the lipoprotein profile in dialyzed patients in order to evaluate the relationship with the accelerated atherosclerosis and vascular accidents. Methods In 102 dialysis patients and 40 non-uremic controls, we investigated the lipoprotein plasma profile, high sensitivity C-reactive protein (CRP), ceruloplasmin and serum amyloid A protein (SAA), and followed patients for 1 year to analyze the risk of acute cardiovascular events. Results Total cholesterol, low-density lipoprotein and high-density lipoprotein plasma levels were significantly lower in uremic patients than controls, whereas CRP, SAA, ceruloplasmin, Lp-PLA2 and their ratio with apolipoprotein A1 were significantly higher. Patients with Lp-PLA2 levels [194 nmol/min/ml had more acute cardiovascular events than patients with lower values.